Participant must have a confirmed germline deleterious BRCA mutation; participants with a BRCA or BRCA classified as variant, suspected deleterious by Myriad Genetics are also eligible for the trial; participants with only a BRCA or BRCA VUS (variant of uncertain significance) are not eligible for this study; if a potential subject is considered high risk for carrying a BRCA/BRCA mutation by National Comprehensive Cancer Network (NCCN) criteria but does not have insurance coverage for testing or if results from available testing options will not be ready in time for enrollment in the study Myriad Genetic Laboratories may cover the cost of the test; genetic testing does not have to be performed by Myriad Genetic Laboratories but a study-specific test request form is available for tests submitted to Myriad; this form may also be used for genetic testing which will be covered by the participants insurance and may lead to more expedited testing
Patients must also meet at least one of the following criteria:\r\n* Triple negative: histologically confirmed primary and/or metastatic site that is estrogen receptor (ER)-negative (=< %), progesterone receptor (PR)-negative (=< %), and HERnegative\r\n* BRCA mutation: previously confirmed deleterious breast cancer , early onset (BRCA) or breast cancer , early onset (BRCA) germline mutation or suspected deleterious BRCA or BRCA germline mutation if the classification being used is the -tier classification; documentation of germline test results are required
Patients must have adequate tissue available and must agree to have specimens submitted for germline BRCA deoxyribonucleic acid (DNA) sequencing and other correlative studies\r\n* NOTE: Blood for BRCA mutation testing is to be collected and submitted after registration but before treatment
Documented germline mutation in BRCA or breast cancer , early onset (BRCA) that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function); local germline (g)BRCA testing results, if available, will be used for establishing eligibility; if local gBRCA testing results are not available, central testing will be provided for those patients who otherwise appear to be eligible
Patients who do not have deleterious or suspected deleterious gBRCA and/or  mutations but only have BRCA and/or BRCA mutations that are considered to be non-detrimental (e.g., variants of uncertain clinical significance or variant of unknown significance or variant, favor polymorphism or benign polymorphism etc.)
BRCA /- associated metastatic breast carcinoma
BRCA /-associated metastatic breast carcinoma: at least one but no more than three prior chemotherapy-containing lines.
Documented germline mutation or somatic mutation (or homozygous deletion) in one of the DNA repair genes listed below that is deleterious or suspected to be deleterious; the mutation must be identified through a Clinical Laboratory Improvement Act (CLIA)-approved next generation sequencing (NGS) panel\r\n* Cohort : Germline mutation in one of the DNA repair genes listed below OR\r\n* Cohort : Somatic mutation or homozygous deletion in one of the DNA repair genes listed below or a somatic mutation of BRCA or BRCA (without germline BRCA  / mutation) \r\n* DNA Repair Gene List: ATM, ATR, BARD, BRIP (FANCJ), CHEK , FANCA, FANCC, FANCD, FANCE, FANCF, FANCM, MREA, NBN, PALB, RAD, RADC, RADD, plus other hormone receptor (HR)-related genes at the discretion of Dr. Tung with the key study collaborators \r\n** All deep (homozygous) deletions, frameshift mutations and truncating mutations in the genes listed above are eligible as well as missense variants in these genes that have previously been reported as pathogenic or likely pathogenic
Germline BRCA or BRCA mutation
Have biopsiable and evaluable disease. Note: biopsy is optional for patients known to harbor a BRCA/ mutation
In Part B, the patients recruited to one of the eight expansion arms must have advanced solid tumors of the following types: Arm : Patients with relapsed, platinum-sensitive high grade epithelial, non-mucinous, ovarian cancer, fallopian tube, or primary peritoneal cancer must meet the following criteria: i. Patients must have at least  prior platinum-containing treatments in any treatment setting.  Note: patients could have received additional therapy after the last platinum-containing regimen if the other eligibility criteria are met. ii. Patients must have platinum-sensitive recurrent disease and must not have progressed (by RECIST v. criteria) within  months of the completion of the last platinum containing regimen.  Note: patients can receive additional non-platinum based chemotherapy for recurrence after the last platinum containing regimen if the criteria for platinum sensitivity are met. iii. Arm a: Patients with relapsed, platinum-sensitive high grade epithelial, non-mucinous, ovarian cancer, fallopian tube, or primary peritoneal cancer (EOC) with either known deleterious or suspected deleterious germline or somatic BRCA/ mutations or with DNA HRD  If HRD or BRCA/ mutation status is unknown or has not been previously evaluated, then the patient must undergo tissue screening using the Myriad myChoice diagnostic test to determine eligibility. iv. Arm b: Patients with relapsed, platinum-sensitive high grade epithelial, non-mucinous, ovarian cancer, fallopian tube, or primary peritoneal cancer (EOC) without either known deleterious or suspected deleterious germline or somatic BRCA/ mutations or without DNA HRD  If HRD or BRCA/ mutation status is unknown or has not been previously evaluated, then the patient must undergo tissue screening using the Myriad myChoice diagnostic test to determine eligibility. Arm : Patients with triple negative breast cancer must meet the following criteria: i. Patients with either known deleterious or suspected deleterious germline or somatic BRCA/ mutations or with DNA HRD.  If HRD or BRCA/ mutation status is unknown or has not been previously evaluated, then the patient must undergo tissue screening using the Myriad myChoice diagnostic test to determine eligibility. ii. Patients with - prior platinum-containing treatment in any treatment setting.  Note: patients could have received additional therapy after the last platinum-containing regimen if the other eligibility criteria are met. iii. Patients who have received ?  prior lines of therapy in the advanced or metastatic setting. Arm : Patients with metastatic castration-resistant prostate cancer, including but not limited to mutations in HR pathways and/or defined by HRD algorithms, and must meet the following criteria: i. Patients with either known deleterious or suspected deleterious germline or somatic BRCA/ mutations or with DNA HRD.  If HRD or BRCA/ mutation status is unknown or has not been previously evaluated, then the patient must undergo tissue screening using the Myriad myChoice diagnostic test to determine eligibility. ii. The patient may be either chemotherapy-nave, but must have received prior abiraterone acetate and/or enzalutamide treatment, or have previously had no more than two taxane-based chemotherapy regimens including docetaxel and carbazitaxel. If docetaxel is used more than once, this will be considered as one regimen. iii. At least  weeks since the completion of prior flutamide, bicalutamide, and nilutimide, or enzalutamide and abiraterone treatment. iv. At least  weeks from any radiotherapy, with the exception of a single fraction of radiotherapy for the purposes of palliation (confined to one field). v. Documented prostate cancer progression with one of the following:
Olaparib\r\n* Patients with solid tumors that harbor DNA damage repair gene mutations as exemplified below detected by next-generation sequencing (NGS) or real-time- polymerase chain reaction (RT-PCR) in assays performed at a CLIA-certified laboratory:\r\n** Examples of DNA damage repair deficiency BRCA-ness (somatic mutations in tumors), but not limited to, are: breast cancer , early onset (BRCA ), breast cancer , early onset (BRCA)/Fanconi anemia group D (FANCD), partner and localizer of BRCA (PALB or FANCN), RAD recombinase (RAD), RAD homolog, DNA repair protein (RAD), BRCA interacting protein C-terminal helicase  gene (FANCJ), Fanconi anemia complementation group D (FANCD), S proteasome complex subunit DSS (DSS), MRE homolog A, double strand break repair nuclease (MRE), RAD double strand break repair protein (RAD), nibrin (NBS), Bloom syndrome RecQ like helicase (BLM), ATM serine/threonine kinase (ATM), ATR serine/threonine kinase (ATR), checkpoint kinase  (CHK), checkpoint kinase  (CHK), Fanconi anemia complementation group (FANC) A,-B,-C, -E, -F, -G,-L, M, D
Patients with known germline BRCA mutations will be excluded from the study, however testing is not required for inclusion in the study
Patients must have histologically confirmed solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective, and for which: a) there is reasonable expectation of response to the combination of carboplatin/paclitaxel OR b) breast cancer (BRCA) / germline mutation is present; results from Myriad will be acceptable; if testing for BRCA  and  germline mutations is done through another organization, a report from a genetics consult with a qualified medical professional confirming that the laboratory results show a recognized germline deleterious BRCA  or  mutation or rearrangement is required; if the latter cannot be obtained, principal investigator (PI) or study chair review of the lab results and confirmation of BRCA mutation or rearrangement will be required OR c) BRCA / somatic mutation previously identified using a Clinical Laboratory Improvement Amendments (CLIA) certified assay
Incurable advanced solid tumors that are no longer responding to conventional therapy or for which no effective therapy exists; at the RD of Part , an extension cohort up to  patients with metastatic breast cancer who are known to be BRCA mutation carriers will be enrolled.
Cohorts  to : Have platinum-resistant disease and have documented test results assessing alterations in the BRCA and BRCA genes prior to receiving study treatment.
Cohort : Are BRCA positive and have previously received a PARP.
Patients with a deleterious or suspected deleterious BRCA or BRCA mutation (germline or somatic)
Have a deleterious mutation in BRCA/ or ATM, or molecular evidence of other homologous recombination deficiency
Patients known to have a BRCA gene mutation; genetic testing is not required
Patients with clear cell or low grade ovarian cancer unless the patient has a known germline or somatic breast cancer (BRCA) mutation or a mutation in another homologous recombination gene
Solid tumors with one or more of the following DNA repair defects:\r\n* BRCA, BRCA, ATM, BARD, BRIP, CDK, CHEK, FANCA, NBN, PALB, RAD, RADB, RADC, RADD, RADL (validated from archival tumor tissue or germ line testing from any Clinical Laboratory Improvement Act [CLIA] approved lab); this testing should occur prior to study consent or enrollment
Eligible patients with germline or somatic BRCA mutations must have disease progression after treatment with a PARP inhibitor; patients with unknown BRCA status must undergo testing prior to enrollment; however, non-mutation patients will also be eligible for study
Patients PRE-identified as having either a germline deleterious mutation or tumor expression of a deleterious mutation) as determined by next-generation DNA sequencing only, in at least one gene involved in DNA damage repair through homologous recombination including but not limited to: ARIDA, ATM, ATRX, MREA, NBN, PTEN, RAD//B, BARD, BLM, BRCA, BRCA, BRIP, FANCA/C/D/E/F/G/L, PALB, WRN, CHEK, CHEK, BAP, FAMA, SLX, MLL or XRCC\r\n* Patients with somatic mutations will be PRE-identified as having a homologous recombination mutation based on next-generation sequencing (NGS) done in a Clinical Laboratory Improvement Act (CLIA) certified, College of American Pathologists (CAP) tested and bioinformatics-validated testing lab PRIOR to enrollment in this current protocol; the testing may have been done at any time prior to enrollment; HOWEVER, if any patient has had NGS testing more than  months prior to enrollment, or if there has been intervening therapy, then a repeat NGS test must be done and the deleterious somatic mutation must be re-identified for inclusion\r\n** The determination of a deleterious mutation must be supported in the documentation included in the testing, and should include clinical, or pre-clinical literature to support the finding that a specific mutation results in impaired function of the gene, and thus impaired DNA repair through homologous recombination; variants of unknown significance will not be eligible\r\n* Patients with germline deleterious mutations may have been identified at any time point prior to inclusion in the protocol and do NOT need to have this genetic testing repeated regardless of time frame and intervening therapy
Subjects must not be a known carrier of BRCA or BRCA gene mutation
For enrichment stage of trial only (if necessary): Confirmation of a suspected/known deleterious mutation in a gene of interest (ATM, BARD, BRCA, BRCA, BRIP, CDK, CHEK, CHEK, FANCL, PALB, PPPRA, RADB, RADC, RADD or other DNA repair genes) via Clinical Laboratory Improvement Act (CLIA) certified testing
Patients must be germline BRCA  or  negative; (Note: if BRCA status was previously determined, that result is acceptable but documentation of status must be available; subjects with unknown status will be referred to genetic counselling for BRCA testing as per standard of care) and/or patients with previously identified genetic aberrations that are associated with HRD will be eligible even in the absence of family history [e.g. somatic BRCA mutation, Fanconi Anemia gene, ATM or RAD mutations]
Patients must have clear and documented evidence of biallelic inactivation BRCA, BRCA or ATM by sequencing, for example University of Washington (UW)-Oncoplex, SUC, or Foundation One testing and/or patients with clearly deleterious mutations of other genes involved in homologous DNA repair (e.g., partner and localizer of BRCA [PALB], BRCA-interacting protein  [BRIP], etc.) by sequencing via UW-Oncoplex, SUC, or Foundation One testing may be included at the investigators discretion
Patients with cytologically or histologically confirmed locally advanced or metastatic pancreas adenocarcinoma with a BRCA or  or PALB mutation confirmed by report from Myriad Genetics (United States of America [USA]); reports from other molecular diagnostic companies can be used to confirm mutations as well; BRCA  or  or PALB mutation can be confirmed locally for all international sites\r\n* For Part I, non-randomized, lead-in portion, patients with a known BRCA  or  or PALB mutation are eligible along with patients who potentially may have a likelihood of having a BRCA mutation (e.g., personal or family history of breast, pancreas, ovary, endometrial, prostate or other likely related malignancy); for Part I, randomized portion, a known BRCA  or  or PALB mutation is required
PHASE II STUDY COHORT  OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C): Documentation of germline breast cancer (BRCA) and BRCA mutation (gBRCAm) status will be requested; a documented deleterious germline BRCA and BRCA mutation (gBRCAm) obtained in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory will be requested, but it is not mandated for enrollment; Myriad testing will be accepted; if testing for BRCA is done by other organizations either by multi-gene panels or individual testing, genetic consultation report from a qualified medical professional listing the mutation and confirming that the laboratory results showed a recognized gBRCAm or germline deleterious BRCA rearrangement is required; if the patient refused genetic counseling, it should be documented in the medical records; variants of uncertain significance (VUS) of BRCA and BRCA are not considered deleterious; patients with VUS or deleterious mutation in other genes without gBRCAm or patients with negative BRCA testing are still eligible
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY)\r\nDocumentation of germline BRCA and BRCA mutation (gBRCAm) status will be requested for eligibility; a documented deleterious gBRCAm obtained in a CLIA-certified laboratory, including but not limited to Myriad Genetics, either by multi-gene panels or individual testing, will be required prior to study enrollment; variants of uncertain significance (VUS) of BRCA and BRCA are not considered deleterious mutation; patients with VUS or deleterious mutation in other genes without gBRCAm or patients with negative BRCA testing are still eligible
Patients must have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers; patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) high-risk histologies are also eligible, provided that the patient has a known deleterious germline BRCA or BRCA mutation identified through testing at a clinical laboratory; Note: Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing will be accepted; if testing for germline BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germline deleterious BRCA or BRCA mutation or BRCA rearrangement is required; please collect a copy of Myriad or other BRCA mutational analysis (positive or VUS or negative) reports\r\n* Platinum-sensitive disease defined as no clinical or radiographic evidence of disease recurrence for >  months (or  days) after last receipt of platinum-based therapy\r\n* Patients must have had a complete clinical response to their prior line of platinum therapy and cannot have had progression through prior platinum-based therapy
No deleterious or suspected deleterious germline BRCA or BRCA mutation based on full sequencing and comprehensive rearrangement testing at an external reference laboratory; patients with variants of unknown significance will be eligible
Deleterious or suspected deleterious germline or somatic gene mutation implicated in the HR pathway, excluding BRCA or BRCA, based on multiplex germline gene testing or direct tumor next generation deoxyribonucleic acid (DNA) sequencing; these genes include: PTEN, PALB, CHEK, ATM, NBN, BARD, BRIP, RAD, RADC, RAD, RADD, MRE, ATR, Fanconi anemia complementation group of genes (FANCA, FANCC, FANCD, FANCE, FANCF, FANCG, FANCL), plus other HR-related genes at the discretion of the primary investigators
Any patient with a deleterious mutation in BRCA or BRCA
Known BRCA  or BRCA  mutation.
BRCA, BRCA and/or ATM gene defect.
The presence of homologous recombination deficiency defined by either; A) Inherited pathogenic variant of BRCA, ATM, BRCA, PALB by a Clinical Laboratory Improvement Act (CLIA) level germline assay or B) have evidence by somatic sequencing using a CLIA level assay of biallelic inactivation of BRCA, BRCA, PALB, FANCA or biallelic inactivation or monoallelic inactivating mutation of ATM.  It is anticipated that the majority of patients will be germline carriers of a pathogenic variant of BRCA, BRCA or ATM.
Germline BRCA / Mutation Positive
Documented evidence of at least ONE or MORE of the following:\r\n* Biallelic inactivation of genes involved in homologous recombination repair in the tumor\r\n* Biallelic inactivation of other genes involved in homologous DNA recombination repair in the tumor may be included at investigators discretion\r\n* Homologous recombination repair deficiency by genomic signature in the tumor\r\n* Clearly pathogenic or likely pathogenic germline mutation in BRCA, BRCA and/or ATM\r\n* (Note: the following are not alone sufficient for eligibility and require additional criteria to be met: germline variant of uncertain significance in BRCA, BRCA and/or ATM; germline mutations in other HR genes)
Patients with HRD identified by one of the following criteria: a) Tested positive for BRCA  or  germline deleterious mutation, b) Previously identified genetic aberrations that are associated with HRD (e.g., somatic BRCA mutation, PALB, Fanconi anemia gene or RAD mutations), c) Patients with somatic ATM loss as identifiable with immunohistochemistry or with ATM mutation, d) Pancreatic ductal adenocarcinoma (PDAC) patients with family history of  or more first-degree relatives with BRCA-associated cancers (stomach, breast, ovary) or  or more first-degree relative with PDAC
Phase II only: Patients with metastatic adenocarcinoma of the pancreas with genomic markers (signature) of homologous recombination deficiency (HRD) or BRCA or BRCA or PALB mutation, or HRD (non-BRCA, non-PALB) who have not received any systemic therapy in the metastatic setting\r\n* NOTE: In pancreatic cancer: exposure to irinotecan is only allowed in the neoadjuvant setting and no progressive disease <  months from last dose of irinotecan
Breast cancer in BRCA or BRCA positive ovarian cancer patients.
For the dose expansion cohort, patients with triple-negative breast cancer may not be BRCA/ germline mutation carriers
Documented mutation of tumor protein  (TP), breast cancer (BRCA), BRCA, or other hereditary cancer syndromes
For expansion cohort patients, the profiling must reveal at least one mutation in the following selected DNA repair genes involved in cell cycle arrest signal transduction, BRCA pathway, Fanconis proteins pathway, and RAD pathway: (ATR, ATM, CHEK, CHEK, BRCA, BAP, BARD, FANCD, FANCE, FANCC, RAD, FANCA, RAD, BRCA, PALB, CDK [ENSG, also known as CRK, CRKR, CRKRS], POLE, POLD, BRAC, PRKDC, ERCC, POLQ, MREA, NBN [MBS]), or at least one gene amplification in FANCD, FANCE, FANCC, FANCA, Corf (EMSY)\r\n*NOTE: Tissue or blood cell free DNA are allowed for genomic profiling of tumor; profiling should have been performed at a Clinical Laboratory Improvement Act (CLIA) certified lab =<  year prior to registration\r\n* NOTE: Patients in the dose escalation phase are not required to have such mutations; although genomic profiling is not required for dose escalation patients, it is encouraged in these patients prior to or after study registration if feasible
Patients with deleterious BRCA / mutated ovarian cancer are not eligible
TREATMENT: Patients with metastatic breast cancer and BRCA mutations must have received specific PARP inhibitor therapy; if these patients have other mutations of interest as defined in the protocol, they will be eligible to receive agents based on that mutation
Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings; both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers; patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided that the patient has a known deleterious germline BRCA or BRCA mutation identified through testing at a clinical laboratory\r\n* Note: Due to the long acceptance of BRCA testing through Myriad, Myriad testing will be accepted; if testing for BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germ line deleterious BRCA  or BRCA  mutation or BRCA rearrangement is required; a copy of Myriad or other BRCA mutational analysis (positive or variants of unknown significance [VUS] or negative) reports will be requested but not required for study enrollment
Known BRCA/ status is not required for study entry; however patients known to have a germline deleterious BRCA/ mutation should be encouraged to consider a preoperative trial specifically designed for BRCA/ carriers, if available
If an ovarian cancer patient has a different histology than HGSC, but has a known germline BRCA or BRCA mutation and meets all other criteria listed, that patient is eligible
Phase I: Patients must have received at least one prior chemotherapy regimen for metastatic disease; patients with deleterious germ line mutations in breast cancer (BRCA) or BRCA are not required to have received prior chemotherapy for metastatic disease
All potential subjects should be evaluated for whether breast cancer (BRCA)- testing is medically appropriate; individuals who have a % or higher risk of having a BRCA- mutation (Myriad tables at www.myriad.com) are encouraged (but not required) to have mutation testing and results known; information regarding mutation status (positive [including specific mutation], negative, or unknown) and projected risk of having a mutation (as determined by Myriad tables) will be collected at the time of diagnosis
Patients must be assigned to SG; SG biomarker eligibility defined as homologous recombination repair deficiency (HRRD) positive is as follows\r\n* Biomarker-positive group\r\n** HRRD by FMI\r\n*** Homologous recombination repair deficiency by Foundation Medicine Inc., criteria\r\n* Alteration type\r\n** Truncating mutation, frameshift deletions, indels missense and nonsense mutations predicted to have functional consequence in any of the specified genes\r\n* Eligible alteration\r\n** Mutation in any one of the following critical HRR pathway genes: ATM, ATR, BARD, BRCA, BRCA, BRIP, CHEK, CHEK, FANCA, FANCC, FANCD, FANCF, FANCM, NBN (NBS), PALB, RAD, RADB (RADL), RADL, RPA
Suspected deleterious or deleterious BRCA and/or BRCA germline mutation.
Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA or BRCA mutation from Myriad Genetics or other laboratory approved by the Sponsor
Prior BRCA-associated cancer as long as there is no current evidence of the cancer
Have a known BRCA / mutation status (for participants who do not have a known BRCA / status at screening, a blood sample will be collected to determine the status with the results available prior to randomization
Known deleterious germline mutation of BRCA/ (Patients in Cohorts A and A)
Documented germline mutation in Breast Cancer susceptibility genes: BRCA and/or BRCA that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)
BRCA  and/or BRCA mutations that are considered to be non detrimental
Documented Breast Cancer Gene (BRCA) germline mutation testing.
Identified deleterious mutation in BRCA  or  genes (this does not include variants of uncertain significance)
Deleterious or pathogenic germline BRCA  or BRCA  mutation
Germline BRCA or BRCA mutation; patients with unknown BRCA status who meet NCCN BRCA screening criteria will be screened for BRCA mutation.
Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER-) invasive breast cancer, stage I-III at diagnosis (AJCC th edition) based on initial evaluation by clinical examination and/or breast imaging. NOTE: Patients with ER+ and/or PR+ may enroll ONLY if they are known carriers of a deleterious mutation in BRCA or BRCA. Patients with HER+ tumors may not enroll regardless of BRCA status.
Have a deleterious mutation in a BRCA/ or ATM gene
No evidence of deleterious or suspected deleterious germline mutation in BRCA or BRCA genes
BRCA / mutation; Note: Patients are not required to undergo BRCA and BRCA or other genetic mutation tests in order to enroll on the study. However, in the event a patient is tested and is found to be a mutation carrier, she would be excluded from the study
Dose expansion cohort only: Histological or cytological confirmation of advanced unresectable solid tumors for which no standard therapy is available in patients with a known BRCA germline mutation or those with metastatic triple negative breast cancer without known BRCA mutation; for the paclitaxel cohorts, any solid tumors with potential benefit from this combination and paclitaxel
Participants must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either high grade serous or high grade endometrioid cancer based on local histopathological findings; participants with a deleterious BRCA-mutation on a commercial Clinical Laboratory Improvement Amendments (CLIA) assay with other high-grade histologies are also eligible\r\n* Myriad testing will be accepted as documentation of a deleterious mutation; if testing for BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results show a recognized germline deleterious BRCA or BRCA mutation or BRCA rearrangements is required to document the presence of a deleterious mutation
Patients must have one of the following: somatic mutations or deletions in BRCA or BRCA; genomic alterations in other BRCA pathway genes (subcohorts: a. ATM, b. PALB, c. other genes, e.g. Fanconi Anemia genes, ARIDA, MER, RAD, NBS, ATR; amplification of EMSY); or germline mutation in BRCA or BRCA  (not breast or ovarian cancer)
Patients who have endometrial carcinosarcoma; patients with ovarian cancer who have histology other than high-grade serous in the absence of a deleterious BRCA mutation; if the patient has a deleterious BRCA mutation, any histology will be accepted
Subjects must agree to undergo genetic counseling and breast cancer (BRCA) testing; patients in the expansion cohort must have a germline BRCA  or  mutation
Germline mutation in BRCA or BRCA that is predicted to be deleterious or suspected deleterious.
Documented mutation in BRCA or BRCA that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).
BRCA  and/or BRCA mutations that are considered to be non detrimental (e.g., \Variants of uncertain clinical significance\ or \Variant of unknown significance\ or \Variant, favor polymorphism\ or \benign polymorphism\ etc.)
Documented mutation in BRCA or BRCA that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).
BRCA and/or BRCA mutations that are considered to be non detrimental (e.g. \Variants of uncertain clinical significance\ or \Variant of unknown significance\ or \Variant, favor polymorphism\ or \benign polymorphism\ etc).
Must have a documented deleterious Breast Cancer Gene BRCA or BRCA germline mutation.
Have a known deleterious BRCA mutation (gBRCA or sBRCA) (as determined by a local laboratory that has received an international or country-specific, quality standards certification)
Subjects who are BRCA positive.
Advanced breast cancer with positive BRCA or BRCA status
Recurrent, and/or metastatic germline BRCA / mutation-associated ovarian cancer, with progression on a PARP inhibitor monotherapy after attaining a response to that PARPi (CR, PR, or stable disease [SD] >=  months [mo])
Integral biomarkers: all patients who are eligible for the study due to a history of positive BRCA/ mutation must provide documented evidence of their deleterious germline mutation status, obtained in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory, including but not limited to Myriad Genetics prior to study enrollment; variants of uncertain significance (VUS) of BRCA/ and BRCA/ somatic mutations are not considered deleterious germline BRCA/ mutations; due to the long acceptance of BRCA  and BRCA  mutation testing through Myriad, Myriad results will be acceptable; if testing for BRCA  and BRCA  mutation is done by other organizations, a genetic consultation report from a qualified medical professional confirming that the laboratory results showed a recognized germ line deleterious BRCA  or BRCA  mutation or deleterious BRCA  rearrangement is required
Cancer in a patient with a known inherited susceptibility mutation in breast cancer (BRCA) or BRCA
Part  and : Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective. Subjects must also ) have a documented BRCA or BRCA mutation that is considered to be deleterious by the investigator, OR ) have high grade serous ovarian, fallopian tube, or peritoneal cancer. Subjects with molecular features indicative of DNA repair defects (such as mutation in the Fanconi anemia pathway genes or methylation of the BRCA promoter) may be considered eligible for following discussion with the medical monitor. Part : Histologically or cytologically confirmed breast, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective. Platinum-resistant ovarian cancer is not permitted. Subjects must also ) have a documented BRCA or BRCA mutation that is considered to be deleterious by the investigator and ) have received  or fewer regimens of cytotoxic chemotherapy in the metastatic setting and ) have evaluable disease as defined by RECIST . or GCIC-CA- criteria.
A first-, second-, or third-degree relative (e.g., son, brother, nephew, or cousin) of an individual with a documented BRCA or BRCA pathogenic variant
Family history suggestive of a hereditary cancer syndrome not attributable to the BRCA or BRCA mutation in their family, based on pedigree review by the study team
An uncertain risk of carrying the familial BRCA or BRCA mutation (e.g., because it is not clear on what side of the family the mutation is segregating), based on pedigree review by the study team
Have one or more children who are BRCA or BRCA positive
Additionally, patients that have a high risk of breast cancer and are pursuing prophylactic mastectomies (for example BRCA mutation carriers) will also be considered
Women who are known to be positive for the breast cancer (BRCA) mutation
Have a known cancer gene mutation (such as breast cancer /, early onset [BRCA /])
Decided to have blood drawn for breast cancer, early onset gene (BRCA) / syndrome testing
Have one blood relative with a mutation in BRCA, BRCA, BRIP, PALB, RADC, RADD, BARD, MSH, MSH, MLH, or PMS
Have a personal or family history of any hereditary/genetic cancer syndrome such as BRCA and BRCA polymorphisms, hereditary nonpolyposis colon cancer, or familial adenomatous polyposis
Known to be at high risk for breast cancer due to known or suspected pathologic BRCA mutation (i.e. first-degree relative with known mutation) or prior chest radiation therapy before age 
BRCA  or  mutation
Have a known high penetrance mutation associated with hereditary breast or ovarian cancer (including BRCA, BRCA, p, PTRN, ATM, PALB, mutations associated with the Lynch Syndrome, etc.)
PILOT II: BRCA positive OR Lynch syndrome positive individuals
A known deleterious mutation in BRCA, BRCA, PTEN, or TP. (Note: The participant must be a documented carrier to meet this criterion. If there is a known mutation in a hereditary breast cancer susceptibility gene in a participant's family member, the participant herself must have undergone genetic testing as per National Comprehensive Cancer Network guidelines to be eligible per this criterion.)
Modified Gail/CARE model risk at  years ? .%. (Note: Risk models are to be used only if there is no known previous diagnosis of resected ductal carcinoma in situ [DCIS] or LCIS and there is no known deleterious mutation in BRCA, BRCA, PTEN, or TP)
% or more probability of BRCA mutation by BRCAPRO or similar model
Documented germline pathogenic or likely pathogenic variant in the BRCA or BRCA genes
Known carrier of a BRCA or  mutation
Women seeking an RRSO or RRS at MSK, including breast cancer  (BRCA )/breast cancer  (BRCA) mutation carriers and women with a strong family history of breast and or/ovarian cancer
Subject has BRCA  or  mutations. Note: Testing will only be required for Subjects presenting with bilateral breast cancer; testing is not required for unilateral cancers
Patients with known breast cancer (BRCA) mutations; patients who are not tested or whose testing result is not returned at the time of registration are not excluded from registering to this study
Patients enrolling in the BRCA-deficient cohorts must have a documented BRCA or BRCA germline mutation; alternatively, patients with tumors harboring somatic BRCA mutations may also enroll after discussion with the principal investigator
Premenopausal women with a documented BRCA or BRCA mutation; menopause is defined as >=  months of amenorrhea
Women without a documented BRCA mutation
No patients with known deleterious mutations in breast cancer (BRCA) genes
Participants with a known BRCA  or  mutation
Participants with a known breast cancer (BRCA)  or  mutation
Negative for BRCA and BRCA mutations
Patients must not have known deleterious mutations in breast cancer (BRCA) genes